Nexia Biotechnologies Inc. English version Français
Technology Corporate Information Biology Fundamentals Human Resources Investor Relations

Goat

Nexia Biotechnologies Ltd.
P.O. BOX 187
Branch Jean-Talon
Montreal, Quebec, Canada
H1S 2Z2

Phone: 780-486-2317
Fax: 514.371.7880

Contact Nexia


Important documents

Fiscal 2007 Annual Report

Nexia in the News

National Post - Oil and gas could get Nexia's goat

Technology

Protexia

Protexia™ is a recombinant form of human butyrylcholinesterase (BChE), a naturally occurring protein found in minute quantities in blood. BChE functions as a natural bioscavenger, like a sponge, to absorb toxins such as organophosphate poisons (OP), nerve agents and certain pesticides, before they cause neurological damage. Studies performed by the U.S. military, using plasma-derived BChE, have indicated that increasing BChE concentrations in the blood protects laboratory animals from the toxic effects of nerve agents. While the potential utility of BChE has been known for over a decade, a major limitation on its widespread use has been the inability to produce it in commercial volumes. Nexia believes that its transgenic production technology can overcome this limitation.



Abstracts

Preclinical Milestones
Completed
Milestone I Broad Spectrum - demonstrated effective in vitro binding and neutralization by Protexia™ of a variety of nerve agents, including soman, sarin, VX and tabun. November 20, 2003
Milestone II Effective - a series of in vivo challenge studies with nerve agents - demonstrated clearly that Protexia™ was efficacious as a medical countermeasure in animal models. January 22, 2004
Milestone III Drug Dynamics - involved pharmacokinetics (PK) studies showing that a single injection of Protexia™ resulted in a sustained elevation of blood BChE levels for many hours. Further, regarding distribution of Protexia™ within the body, the PK data shows that Protexia™ concentrates in the blood stream. Retention in the blood is critical because it is here that Protexia™ bioscavenges nerve agents that principally gain access to the body's nervous system via the blood. April 13, 2004

Nerve Agents

Nerve agents are extremely toxic chemicals that attack the nervous system. They were first developed as insecticides in the 1930s. Their potency was recognized during World War II, and they were developed as nerve agents for use in chemical warfare. Most recently, terrorists have deployed nerve agents as a weapon. One of the most tragic incidents occurred in 1995 when sarin was released in the Tokyo subway system, injuring thousands and killing 12.

Nerve agents enter the blood stream via inhalation (tabun, sarin, soman) or absorption through the skin (VX). They travel from the blood to the brain and interrupt nerve-to-nerve function, thereby causing massive convulsions and death in severe cases. Symptoms occur rapidly upon inhalation of nerve agent vapour or may be delayed for hours for skin exposure. There are treatments available but they must be administered quickly after exposure. After severe exposure, permanent damage to the central nervous system frequently occurs.

Nexia Uses Biomimicry

One of Nexia's founding principles is to seek out what Mother Nature has perfected over millions of years and mimic that engineering in Nexia's recombinant transgenic platform. This is known as biomimcry. In the world, BChE is naturally found to scavenge toxins in the environment. The bioscavenging nature of enzymes like BChE protects certain animals, such as rats and mice, from toxins in their natural habitat. Using biomimicry, Nexia is investigating the use of rBChE to protect humans from the toxic effects of nerve agents.


 >Technology >Products